New York, NY (PRWEB) February 6, 2006
Heart valve disease will be the focus of the annual conference of the Heart Valve Society of America (HVSA). The event, Valvular Heart Disease: New Strategies will provide state-of-the-art information on diagnosis and treatment of this emerging public health problem. Sponsored by the Mayo Clinic Department of Medicine, the conference will be held from May 14 – 17, 2006 at the Bellagio Resort, Las Vegas, NV.
Valvular heart diseases are among the most prominent causes of heart failure and premature cardiac death. It is estimated that more than 10 million Americans, alone, have some type of heart valve abnormality. In approximately five million, the disease is moderate to severe. Three to four million people will require surgery at some time in their lives. Heart valve disease develops with aging; these numbers will grow as the Baby Boom generation moves to 60 and beyond.
Valvular Heart Disease: New Strategies will provide a comprehensive panorama of the new pathophysiologic insights, diagnostic methods and surgical and medical therapeutic approaches to valvular heart diseases, as well as project new available strategies. This emerging information will be presented by cardiologists and cardiothoracic surgeons who are world-renown in the field.
Formal lectures, panel discussions, extensive case studies and accessible faculty members will facilitate the exchange of information. The course is designed for U.S. and international medical professionals involved in the diagnosis, evaluation and management of valvular heart disease — cardiologists, cardiothoracic surgeons, internists, pathologists, fellows, nurses and physician assistants.
Course highlights include:
§ Current criteria for surgical intervention
§ Cell and molecular biology of valve disease
§ Predictors of prognostically important deterioration among common lesions
§ Emerging role of pacemaker therapy for mitral regurgitation
§ Controversial role of drug prophylaxis for asymptomatic patients
§ Current status and results for percutaneous valve replacement and repair techniques
§ Surgical and catheter-based therapy for atrial fibrillation associated with mitral valve disease
§ Anti-coagulation strategy early and late for valve replacement
§ Impact of age on morbidity and mortality in valve surgery; considerations for surgical candidacy
§ Case-based study of valvular disease management
§ Technical how-to for surgical, interventional and imaging procedures
Abstract submissions are being accepted through March 17, 2006.
This is the second conference sponsored by the Heart Valve Society of America (HVSA). The 2007 conference, Valves in the Heart of the Big Apple V: Evaluation & Management of Valvular Heart Diseases 2007 will be held in New York City from April 12- 14, 2007.
HVSA (including the Heart Valve Trialists Society) was founded in November 2004 by nationally and internationally prominent cardiologist and cardiothoracic surgeons in the field of heart valve disease. It’s mission is to promote research; educate medical professionals about the evaluation and treatment of heart valve diseases; serve as an informational resource for government, private industry, healthcare providers, the media and public; and, encourage and facilitate education of future heart valve disease specialists.
Membership is open to medical and allied health professionals involved/interested in the field, as well as individuals who work for corporations, academic and service institutions, and foundations interested in valvular heart disease.
Additional information on the 2006 conference is available by calling 800-283-6296.
# # #